Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

FDA Moves to Pull Tavneos; Liver Safety Signals Trigger EMA and Global Review

Tensions between Amgen and the U.S. Food and Drug Administration have intensified after the regulator raised serious safety concerns regarding Amgen and pushed for its voluntary withdrawal from the market. The FDA pointed to emerging safety signals and post-marketing adverse
  • News
FDA Moves to Pull Tavneos; Liver Safety Signals Trigger EMA and Global Review

Sanofi CIDP Trial Collapses; What Phase 3 Revealed That Phase 2 Missed

Sanofi has discontinued its Phase 3 MOBILIZE study of Sanofi riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis showed the trial was unlikely to demonstrate sufficient efficacy, according to a June 10, 2026 update. The decision followed an
  • News
Sanofi CIDP Trial Collapses; What Phase 3 Revealed That Phase 2 Missed

Quality Manager Requirements in 2026: Quality Systems Ownership, GMP Compliance, and CAPA Control

This article explains the evolving role of a GMP Quality Manager in pharmaceutical operations, focusing on quality system ownership, CAPA management, deviation investigations, and FDA inspection readiness. It highlights key competencies required for effective pharmaceutical quality management systems today.
  • Blog, Quality Management System
GMP quality assurance manager role in pharmaceutical manufacturing showing quality system ownership, CAPA ownership, deviation investigation process, change control oversight, and quality metrics in GMP operations.

China Opens Order 818 Pathway; Gene and Cell Therapies Gain Fast-Track Approval Route

China has launched a new regulatory pathway that could accelerate patient access to advanced biomedical technologies while reshaping global clinical development strategies. The regulation, known as Order 818, took effect on May 1, 2026, and allows selected gene editing therapies,
  • News
China Opens Order 818 Pathway; Gene and Cell Therapies Gain Fast-Track Approval Route

Federal Funding Freeze Pressures U.S. Biotech; State Networks Rush to Stabilize R&D

Life science organizations across the United States are calling for stronger local and state-level support as federal funding delays and policy shifts intensify pressure on biotech companies. In a June 10, 2026 opinion piece, industry leader Jennifer Hawks Bland highlights
  • News
Federal Funding Freeze Pressures U.S. Biotech; State Networks Rush to Stabilize R&D

Risk Management in QMS in 2026: ICH Q9 Framework, GMP Controls, and CAPA Integration

Discover how pharmaceutical companies use ICH Q9 principles, GMP risk assessment, and CAPA integration to strengthen quality oversight, improve inspection readiness, and build effective quality risk management programs that support compliance, patient safety, and continuous improvement in 2026.
  • Blog, Quality Management System
Pharmaceutical quality professionals performing GMP risk assessment and quality risk assessment activities using the ICH Q9 risk management framework

Inside the MASH Power Shift; Rivus Forces HU6 Into High-Stakes Phase 3 Breakthrough

Rivus Pharmaceuticals enters a new development phase as CEO Jorge Bartolome outlines a shift toward late-stage clinical execution in MASH and broader cardiometabolic disease. The company advances its lead asset HU6 into Phase 3 planning while expanding its pipeline in
  • News
Inside the MASH Power Shift; Rivus Forces HU6 Into High-Stakes Phase 3 Breakthrough

Pentagon Labels WuXi AppTec Military Linked; Pharma Supply Chain Shock Intensifies

The U.S. Department of Defense has added WuXi AppTec, a Shanghai-based contract research, development, and manufacturing organization, to its list of “Chinese military companies,” according to a notice set for publication in the Federal Register on June 9, 2026. The
  • News
Pentagon Labels WuXi AppTec Military Linked; Pharma Supply Chain Shock Intensifies